Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRX-102 versus agalsidase beta in Fabry disease with impaired renal function
NL-OMON45301Phase 3Active, not recruiting
- Sponsor
- Protalix BioTherapeutics
- Start
- Oct 2017
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, PEGylated Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Fabry disease (FD) comparing Pegunigalsidase alfa with Agalsidase beta (2 arms). Primary endpoint: Mean annualized change in eGFR. Started Oct 2017; status: active, not recruiting.
02
Drugs
pegunigalsidase alfaagalsidase beta
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NL-OMON45301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45301.